Specialty injectable are used in the treatment of chronic disease like rheumatoid arthritis, human immunodeficiency virus (HIV), infectious diseases, cancer, auto immune disorders, hemophilia and cardiovascular diseases. These specialty injectable are expensive drugs and they require appropriate temperature, clinical management and special handling. This is an expensive drug therapy that requires to be administered by injection. Increase prevalence of chronic diseases is expected to boost the growth of the global specialty market over the forecast period. For instance, Centers for Disease Control and Prevention in the U.S. stated that chronic diseases are the leading cause of disability and 7 of 10 main causes of death.
The global specialty injectable market was valued at US$43.6 Bn in 2021 and is estimated to exhibit a CAGR of 10.2% during the forecast period.
Get Free Sample PDF Copy (Including Full TOC, List of Tables & Figures, Chart) @
Impact of the COVID-19:
Increased use of antibody therapy for treating COVID-19 is expected to drive the growth of the global specialty injectable market during the pandemic. For instance, on October 19, 2021, according to an article by the U.S National Institute of Healthcare mentioned that Anti SARS-CoV2 Monoclonal Antibodies therapy received authorization for emergency use for the treating moderate infection of COVID-19.
Rise in the research and development activities for the development of specialty injectable used for treating chronic diseases like cancer, heart diseases or diabetes by the market key players is expected to boost the growth of the global specialty injectable market during the forecast period. For instance, Merck Sharp & Dohme Corp, a research-based pharma company is currently carrying out their clinical trials of Pembrolizumab injection which can be used for treating Nonsquamous Non-Small Cell Lung Cancer. The drug is in its third phase of trials and the primary study is anticipated to be completed by 2023.
Moreover, rise in the number of approvals of specialty injectable by regulatory authorities for chronic disease like cancer is expected to drive the growth of the global specialty injectable market during the forecast period. For instance, on January 27, 2021, a GSK Healthcare owned pharmaceutical company, ViiV Healthcare received approval for Cabenuva from the U.S. FDA, and this can be used for maintaining viral suspension in HIV patients.
Furthermore, representation of their researches at various conferences by key market players is expected to drive the growth of the global specialty injectable market during the forecast period. For instance, October 7, 2021 Trevi Therapeutics which is a clinical-stage pharmaceutical company developing Haduvi, used for curing chronic cough for people suffering with idiopathic pulmonary fibrosis, a life-threatening neurologically mediated illnesses. Haduvio can also be useful for levodopa-induced dyskinesia, for patients suffering with Parkinson’s disease.
Rise in product recall caused by packaging and transportation errors or issues arising during production are expected to hinder the growth of the global specialty injectable market over the forecast period. For instance, Sanofi, a pharmaceutical company, which develops and manufactures vaccines announced the safety instructions for their Dupixent Injection. Anaphylaxis, asthma, inflammation of blood vessels and eye problems are some of the side effects of the injection.
North America is anticipated to witness robust growth in the global specialty injectable market over the forecast period owing to the increase in product launches. For instance, on October 21, 2021, a pharmaceutical company, Biocon Biologics has launched an interchangeable biosimilar insulin glargine injection, along with Viatris, which is a manufacturer of various therapeutics. The newly developed injection will be helpful for patients suffering from Diabetes Type 1 or 2.
Furthuremore, Europe is expected to witness robust growth in the global specialty injectable market during the forecast period owing to the increase in product availability. For instance, Xeris Biopharma a developer of liquid stable injectable, has signed a supply agreement with Tetris Pharma Ltd on July 19, 2021, for commercialization of Ogluo, used for treating hypoglycemia. Tetris Pharma is known for developing and marketing healthcare products in European region.
Request PDF Brochure with Latest Insights @
Key players active in the global specialty injectable market are Teva Pharmaceutical Industries Ltd, Pfizer Inc, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories, Alnylam Pharmaceuticals IncNovartis AG, Cipla Limited, Mylan N.V, Eli Lilly and Company, Lupin Ltd, Amgen Inc, Baxter International Inc, Sagent Pharmaceuticals Inc, Merck & Co. Inc, Genentech USA Inc, Biogen, Sun Pharmaceutical Industries Ltd, Endo International Plc, Genzyme Corporation, Fresenius SE & Co. KGaA and AstraZeneca.
Reasons to buy this Specialty Injectable Market Report
◘ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Specialty Injectable Market
◘ Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Specialty Injectable Market
◘ Leading company profiles reveal details of key Specialty Injectable Market players emerging five operations and financial performance
◘ Add weight to presentations and pitches by understanding the future growth prospects of the emerging Specialty Injectable Market with five year historical forecasts
◘ Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Specialty Injectable Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Specialty Injectable Market are also given.
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Specialty Injectable Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Specialty Injectable Industry Impact
Chapter 2 Global Specialty Injectable Competition by Types, Applications, and Top Regions and Countries
2.1 Global Specialty Injectable (Volume and Value) by Type
2.3 Global Specialty Injectable (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Specialty Injectable Sales, Consumption, Export, Import by Regions
Chapter 5 North America Specialty Injectable Market Analysis
Chapter 6 East Asia Specialty Injectable Market Analysis
Chapter 7 Europe Specialty Injectable Market Analysis
Chapter 8 South Asia Specialty Injectable Market Analysis
Chapter 9 Southeast Asia Specialty Injectable Market Analysis
Chapter 10 Middle East Specialty Injectable Market Analysis
Chapter 11 Africa Specialty Injectable Market Analysis
Chapter 12 Oceania Specialty Injectable Market Analysis
Chapter 13 South America Specialty Injectable Market Analysis
Chapter 14 Company Profiles and Key Figures in Specialty Injectable Business
Chapter 15 Global Specialty Injectable Market Forecast (2022-2028)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027